Vanguard Group Inc Context Therapeutics Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,744,961 shares of CNTX stock, worth $6.89 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,744,961
Previous 4,502,198
16.82%
Holding current value
$6.89 Million
Previous $9 Million
18.48%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CNTX
# of Institutions
45Shares Held
56.9MCall Options Held
0Put Options Held
0-
Deep Track Capital, LP Greenwich, CT7.42MShares$13.7 Million0.54% of portfolio
-
Nextech Invest Ag7.42MShares$13.7 Million2.37% of portfolio
-
Avidity Partners Management LP Dallas, TX7.42MShares$13.6 Million0.89% of portfolio
-
Great Point Partners LLC Greenwich, CT6.93MShares$12.8 Million6.28% of portfolio
-
Blue Owl Capital Holdings LP New York, NY5.41MShares$9.96 Million3.5% of portfolio
About Context Therapeutics Inc.
- Ticker CNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,966,100
- Market Cap $29.4M
- Description
- Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...